Targeting the protein kinase C family: are we there yet? (Q52579980)

3 May 2018

title

Targeting the protein kinase C family: are we there yet? (English)

1 reference

3 May 2018

2

Christopher J Twelves

1 reference

3 May 2018

author name string

Helen J Mackay

series ordinal

1

1 reference

3 May 2018

publication date

1 July 2007

1 reference

3 May 2018

language of work or name

English

0 references

published in

Nature Reviews Cancer

1 reference

3 May 2018

volume

7

1 reference

3 May 2018

issue

7

1 reference

3 May 2018

page(s)

554-562

1 reference

3 May 2018

publication type of scholarly work

review article

1 reference

Regulation of protein kinase C and role in cancer biology.

cites work

1 reference

Protein kinase C: structure, function, and regulation

31 March 2020

1 reference

Intracellular signaling by hydrolysis of phospholipids and activation of protein kinase C

31 March 2020

1 reference

Signal perception and transduction: the role of protein kinases

31 March 2020

1 reference

Localization of protein kinase C isozymes in cardiac myocytes

31 March 2020

1 reference

Pharmacologic modulation of protein kinase C isozymes: the role of RACKs and subcellular localisation

31 March 2020

1 reference

Identification of PKC-isoform-specific biological actions using pharmacological approaches

31 March 2020

1 reference

Role of diacylglycerol-regulated protein kinase C isotypes in growth factor activation of the Raf-1 protein kinase

31 March 2020

1 reference

31 March 2020

1 reference

Protein kinase C activates the MEK-ERK pathway in a manner independent of Ras and dependent on Raf.

31 March 2020

1 reference

Further evidence that 3-phosphoinositide-dependent protein kinase-1 (PDK1) is required for the stability and phosphorylation of protein kinase C (PKC) isoforms.

31 March 2020

1 reference

Protein kinase C: a novel target for inhibiting gastric cancer cell invasion

31 March 2020

1 reference

Overexpression of protein kinase C betaII induces colonic hyperproliferation and increased sensitivity to colon carcinogenesis

31 March 2020

1 reference

Protein kinase C isozymes in colon carcinogenesis: guilt by omission

31 March 2020

1 reference

Immunological quantitation of phospholipid/Ca2+-dependent protein kinase of human mammary carcinoma cells: inverse relationship to estrogen receptors

31 March 2020

1 reference

Characterization of vascular endothelial growth factor's effect on the activation of protein kinase C, its isoforms, and endothelial cell growth

31 March 2020

1 reference

Protein kinase C: a key factor in the regulation of tumor cell adhesion to the endothelium

31 March 2020

1 reference

MCF-7 breast cancer cells transfected with protein kinase C-alpha exhibit altered expression of other protein kinase C isoforms and display a more aggressive neoplastic phenotype

31 March 2020

1 reference

Ceramide inactivates cellular protein kinase Calpha

31 March 2020

1 reference

A Functional Role for Mitochondrial Protein Kinase Cα in Bcl2 Phosphorylation and Suppression of Apoptosis

31 March 2020

1 reference

PKC-δ is an apoptotic lamin kinase

31 March 2020

1 reference

Regulation of protein kinase B/Akt activity and Ser473 phosphorylation by protein kinase Calpha in endothelial cells

31 March 2020

1 reference

Protein kinase C betaII regulates Akt phosphorylation on Ser-473 in a cell type- and stimulus-specific fashion.

31 March 2020

1 reference

PKC-eta mediates glioblastoma cell proliferation through the Akt and mTOR signaling pathways

31 March 2020

1 reference

Convergence of multiple signaling cascades at glycogen synthase kinase 3: Edg receptor-mediated phosphorylation and inactivation by lysophosphatidic acid through a protein kinase C-dependent intracellular pathway

31 March 2020

1 reference

Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B

31 March 2020

1 reference

Antiangiogenic effects of a protein kinase Cbeta-selective small molecule

31 March 2020

1 reference

Phorbol esters induce multidrug resistance in human breast cancer cells

31 March 2020

1 reference

Prospects for targeting protein kinase C isozymes in the therapy of drug-resistant cancer--an evolving story

31 March 2020

1 reference

Characterization of phosphorylation-defective mutants of human P-glycoprotein expressed in mammalian cells

31 March 2020

1 reference

Protein kinase C-mediated phosphorylation does not regulate drug transport by the human multidrug resistance P-glycoprotein

31 March 2020

1 reference

Anticancer drug-mediated induction of multidrug resistance-associated genes and protein kinase C isozymes in the T-lymphoblastoid cell line CCRF-CEM and in blasts from patients with acute lymphoblastic leukemias

31 March 2020

1 reference

Protein kinase C alpha expression in normal breast, ductal carcinoma in situ and invasive ductal carcinoma

31 March 2020

1 reference

Tumor grade-dependent alterations in the protein kinase C isoform pattern in urinary bladder carcinomas

31 March 2020

1 reference

Protein kinase C alpha expression is inversely related to ER status in endometrial carcinoma: possible role in AP-1-mediated proliferation of ER-negative endometrial cancer

31 March 2020

1 reference

Protein kinase C isoenzyme patterns characteristically modulated in early prostate cancer

31 March 2020

1 reference

Integrative genomic analysis of protein kinase C (PKC) family identifies PKCiota as a biomarker and potential oncogene in ovarian carcinoma.

31 March 2020

1 reference

Immunohistochemical detection of protein kinase C-beta (PKC-beta) in tumour specimens of patients with non-small cell lung cancer

31 March 2020

1 reference

Expression levels of protein kinase C-alpha in non-small-cell lung cancer

31 March 2020

1 reference

The protein kinase C inhibitor CGP 41251, a staurosporine derivative with antitumor activity, reverses multidrug resistance.

31 March 2020

1 reference

Comparison of staurosporine and four analogues: their effects on growth, rhodamine 123 retention and binding to P-glycoprotein in multidrug-resistant MCF-7/Adr cells

31 March 2020

1 reference

Phase I and pharmacokinetic study of PKC412, an inhibitor of protein kinase C.

31 March 2020

1 reference

Inhibition of PMA-induced human T cell proliferation by bryostatin is associated with enhanced degradation of conventional protein kinase C (cPKC): Ca2+ signals restore mitogenic activity without abrogating enhanced cPKC degradation

31 March 2020

1 reference

Activation of the COOH-terminal Src kinase (Csk) by cAMP-dependent protein kinase inhibits signaling through the T cell receptor

31 March 2020

1 reference

Protein kinase C isoforms in normal and transformed cells of the melanocytic lineage.

31 March 2020

1 reference

Effect of PKC412, a selective inhibitor of protein kinase C, on lung metastasis in mice injected with B16 melanoma cells

31 March 2020

1 reference

The multikinase inhibitor midostaurin (PKC412A) lacks activity in metastatic melanoma: a phase IIA clinical and biologic study

31 March 2020

1 reference

Effects of the kinase inhibitor CGP41251 (PKC 412) on lymphocyte activation and TNF-alpha production

31 March 2020

1 reference

LY317615 decreases plasma VEGF levels in human tumor xenograft-bearing mice

31 March 2020

1 reference

The protein kinase Cbeta-selective inhibitor, Enzastaurin (LY317615.HCl), suppresses signaling through the AKT pathway, induces apoptosis, and suppresses growth of human colon cancer and glioblastoma xenografts

31 March 2020

1 reference

Phase I dose escalation and pharmacokinetic study of enzastaurin, an oral protein kinase C beta inhibitor, in patients with advanced cancer

31 March 2020

1 reference

What is the right dose? The elusive optimal biologic dose in phase I clinical trials

31 March 2020

1 reference

Development and validation of a drug activity biomarker that shows target inhibition in cancer patients receiving enzastaurin, a novel protein kinase C-beta inhibitor

31 March 2020

1 reference

The large-scale isolation of bryostatin 1 from Bugula neritina following current good manufacturing practices

31 March 2020

1 reference

Bryostatins: potent, new mitogens that mimic phorbol ester tumor promoters

31 March 2020

1 reference

Bryostatin 1, an activator of protein kinase C, inhibits tumor promotion by phorbol esters in SENCAR mouse skin

31 March 2020

1 reference

Co-induction of lymphokine synthesis by the antineoplastic bryostatins

31 March 2020

1 reference

Effects of bryostatin 1 and other pharmacological activators of protein kinase C on 1-[beta-D-arabinofuranosyl]cytosine-induced apoptosis in HL-60 human promyelocytic leukemia cells

31 March 2020

1 reference

Bryostatin 1 induces apoptosis and augments inhibitory effects of vincristine in human diffuse large cell lymphoma

31 March 2020

1 reference

Phase I study of bryostatin 1 and gemcitabine

31 March 2020

1 reference

Phase I study of bryostatin 1: assessment of interleukin 6 and tumor necrosis factor alpha induction in vivo. The Cancer Research Campaign Phase I Committee

31 March 2020

1 reference

A phase I study of intravenous bryostatin 1 in patients with advanced cancer

31 March 2020

1 reference

A phase I trial of bryostatin 1 in patients with advanced malignancy using a 24 hour intravenous infusion.

31 March 2020

1 reference

A phase II study of bryostatin 1 in metastatic malignant melanoma

31 March 2020

1 reference

Phase I evaluation of ISIS 3521, an antisense oligodeoxynucleotide to protein kinase C-alpha, in patients with advanced cancer

31 March 2020

1 reference

Efficacy and toxicity of the antisense oligonucleotide aprinocarsen directed against protein kinase C-alpha delivered as a 21-day continuous intravenous infusion in patients with recurrent high-grade astrocytomas

31 March 2020

1 reference

Phase II study of PKC-alpha antisense oligonucleotide aprinocarsen in combination with gemcitabine and carboplatin in patients with advanced non-small cell lung cancer

31 March 2020

1 reference

Phase III study of gemcitabine and cisplatin with or without aprinocarsen, a protein kinase C-alpha antisense oligonucleotide, in patients with advanced-stage non-small-cell lung cancer

31 March 2020

1 reference

Coadministration of sorafenib with rottlerin potently inhibits cell proliferation and migration in human malignant glioma cells

31 March 2020

1 reference

A phase I clinical trial of 12- O-tetradecanoylphorbol-13-acetate for patients with relapsed/refractory malignancies

31 March 2020

1 reference

Staurosporine-related compounds, K252a and UCN-01, inhibit both cPKC and nPKC

31 March 2020

1 reference

Enhancement of camptothecin-induced cytotoxicity with UCN-01 in breast cancer cells: abrogation of S/G(2) arrest

31 March 2020

1 reference

UCN-01 selectively enhances mitomycin C cytotoxicity in p53 defective cells which is mediated through S and/or G(2) checkpoint abrogation

31 March 2020

1 reference

Phase I trial of 72-hour continuous infusion UCN-01 in patients with refractory neoplasms

31 March 2020

1 reference

Isoenzyme specificity of bisindolylmaleimides, selective inhibitors of protein kinase C

31 March 2020

1 reference

Phase I trial of the cyclin-dependent kinase inhibitor and protein kinase C inhibitor 7-hydroxystaurosporine in combination with Fluorouracil in patients with advanced solid tumors.

31 March 2020

1 reference

31 March 2020

Identifiers

DOI

10.1038/NRC2168

1 reference

3 May 2018

release_u7g5ihv3cbfa7h6oc5ufvkyhxm

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/u7g5ihv3cbfa7h6oc5ufvkyhxm

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference

3 May 2018